About GD BioPharma
Tianjin GuDui Biopharma Co., Ltd. is an AI-powered biotechnology company industrializing drug discovery for central nervous system, cardiovascular, and autoimmune diseases. Its proprietary platform integrates deep learning and machine learning-based predictive models with a 35 billion small molecule database, independent chemical descriptor algorithms, and advanced AI systems for activity prediction, conformational analysis, and druggability assessment.
The company has secured 6 IND approvals from CDE. GD-11 (acute ischemic stroke) completing Phase III trials and GD-19 (perioperative pain and cancer-related pain)/GD-20 (autoimmune diseases) advancing through Phase I—translating molecular innovation into clinical validation.
Development History
